– USA, MA – Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the appointment of Stephen Berenson to its Board of Directors. Mr. Berenson is a Managing Partner at Flagship Pioneering and previously spent his career as an investment banker at J.P. Morgan.
“Flagship Pioneering continues to view the microbiome as a rapidly emerging and highly promising field with vast therapeutic potential. We were pleased to extend our Seres ownership through a new investment fund, as part of the Company’s recent public equity offering. Stephen’s financial and strategic acumen will be valuable assets to the Seres Board,” said Noubar Afeyan, co-founder and Lead Director of Seres and Chief Executive Officer of Flagship Pioneering.
Eric Shaff, President and Chief Executive Officer of Seres commented, “Having founded Seres within its Flagship Labs unit, Flagship Pioneering has provided valuable long-term support to Seres and we deeply appreciate their continued engagement. Stephen Berenson is a highly accomplished corporate executive, and I am delighted to welcome him to the Board.”
About v
Prior to Flagship, Mr. Berenson spent 33 years in various roles as an investment banker at J.P. Morgan. During his last 12 years at J.P. Morgan, Mr. Berenson was Vice Chairman of Investment Banking, where he focused on providing high-touch strategic advice and complex transaction execution to leading companies across all industries globally. He was the co-founder of J.P. Morgan’s Global Strategic Advisory Council and co-founder of the firm’s Board Initiative. Mr. Berenson also serves on the Board of Directors of Moderna, Inc. and CiBO Technologies, Inc.
“Seres is a clear leader in the development of microbiome therapeutics, and I am very pleased to join the Company’s Board. I am especially excited to join Seres ahead of the important clinical readouts anticipated in 2020, and the potential to create substantial long-term shareholder value while developing important new medicines,” said Mr. Berenson.
Mr. Berenson received an S.B. in mathematics from Massachusetts Institute of Technology.
About Seres Therapeutics
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the state of bacterial diversity and function is imbalanced. Seres’ SER-287 program has obtained Fast Track and Orphan Drug designation from the U.S. Food and Drug Administration and is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres’ SER-109 program has obtained Breakthrough Therapy and Orphan Drug designations from the FDA and is in Phase 3 development for recurrent C. difficile infection. Seres is also developing SER-401 in a Phase 1b study in patients with metastatic melanoma.
For more information: https://www.serestherapeutics.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.